CA2323604A1 - Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides - Google Patents

Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides Download PDF

Info

Publication number
CA2323604A1
CA2323604A1 CA002323604A CA2323604A CA2323604A1 CA 2323604 A1 CA2323604 A1 CA 2323604A1 CA 002323604 A CA002323604 A CA 002323604A CA 2323604 A CA2323604 A CA 2323604A CA 2323604 A1 CA2323604 A1 CA 2323604A1
Authority
CA
Canada
Prior art keywords
plasmid
sequence
composition
coding sequence
interferon alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323604A
Other languages
English (en)
Inventor
Jeff Nordstrom
Federica Pericle
Alain Rolland
Robert Ralston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urigen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2323604A1 publication Critical patent/CA2323604A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une administration et une thérapie géniques, de nouvelles constructions d'acide nucléique permettant d'exprimer l'interféron alpha chez un mammifère, des formulations en vue d'une administration, qui incorporent une construction d'acide nucléique en vue d'une expression, et des procédés de préparation et d'utilisation de ces constructions et de ces formulations. L'invention concerne, en particulier, des constructions de plasmide permettant d'administrer à des cellules un interféron thérapeutique alpha, codant pour des acides nucléiques de façon à moduler une activité tumorale, des procédés d'utilisation de ces constructions (comprenant une thérapie de combinaison avec d'autres agents tels que les cytokines, de préférence IL-12), ainsi que des procédés de préparation de ces constructions.
CA002323604A 1998-03-19 1999-03-12 Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides Abandoned CA2323604A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7865498P 1998-03-19 1998-03-19
US60/078,654 1998-03-19
PCT/US1999/005394 WO1999047678A2 (fr) 1998-03-19 1999-03-12 Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides

Publications (1)

Publication Number Publication Date
CA2323604A1 true CA2323604A1 (fr) 1999-09-23

Family

ID=22145430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323604A Abandoned CA2323604A1 (fr) 1998-03-19 1999-03-12 Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides

Country Status (5)

Country Link
EP (1) EP1064383A2 (fr)
JP (1) JP2002506647A (fr)
AU (1) AU3000399A (fr)
CA (1) CA2323604A1 (fr)
WO (1) WO1999047678A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079289A2 (fr) * 2000-04-14 2001-10-25 Zymogenetics, Inc. Interferon humain, zinf2
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
DE60142971D1 (de) * 2000-07-31 2010-10-14 Biolex Therapeutics Inc Expression biologisch aktiver polypeptide in wasserlinse
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
EP1195436A1 (fr) * 2000-10-04 2002-04-10 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vecteurs d'expression à origine de replication modifiée pour le controle du nombre de copies des plasmides
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
CA2748659A1 (fr) 2003-05-01 2004-11-18 Medgenics Inc. Micro-organes dermiques, leurs procedes et appareils de production et d'utilisation
WO2007084364A2 (fr) * 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Il-12 améliorée aux fins d'expression dans des cellules mammaliennes
WO2008033375A2 (fr) 2006-09-14 2008-03-20 Medgenics Ltd. Formulations de médicament de longue durée
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
WO2009140206A1 (fr) * 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Expression améliorée d'hétérodimères de la famille il-12
JP2013532152A (ja) 2010-06-15 2013-08-15 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
US9272024B2 (en) * 2011-12-12 2016-03-01 The Trustees Of The University Of Pennsylvania Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
EP3600379B1 (fr) 2017-03-31 2022-12-21 Accanis Biotech F&E GmbH & Co KG Prévention et traitement de cancer de la peau non mélanique (nmsc)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
WO1997000321A1 (fr) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Modulateurs de la reponse immunitaire et leur utilisation
WO1997000085A1 (fr) * 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Therapie genique de tumeurs solides au moyen d'interferons seuls ou associes a d'autres proteines immuno-effectrices
EP0904373A1 (fr) * 1996-03-14 1999-03-31 The Immune Response Corporation Apport cible de genes codant l'interferon
JP2001503257A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Ｉｌ―１２遺伝子発現および送達系および使用
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses

Also Published As

Publication number Publication date
JP2002506647A (ja) 2002-03-05
AU3000399A (en) 1999-10-11
WO1999047678A3 (fr) 1999-12-09
EP1064383A2 (fr) 2001-01-03
WO1999047678A2 (fr) 1999-09-23
WO1999047678A9 (fr) 2000-11-09

Similar Documents

Publication Publication Date Title
Toda et al. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
Kramm et al. Gene therapy for brain tumors
US6399588B1 (en) Cancer treatment method utilizing plasmids suitable for IL-2 expression
US6051428A (en) Rapid production of autologous tumor vaccines
Karp et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
US6034072A (en) IL-2 gene expression and delivery systems and uses
CA2323604A1 (fr) Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides
AU675948B2 (en) Bystander effect tumoricidal therapy
JPH10513362A (ja) 生体活性な融合タンパク質および先在する腫瘍の治療
Tamura et al. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer
WO1998034952A9 (fr) Expression du gene il-2, systemes d'administration et utilisations
KR102056066B1 (ko) 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물
Shi et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF
Herrmann Cancer gene therapy: principles, problems, and perspectives
CA2337496A1 (fr) Systemes d'administration et plasmides anti-angiogenese et leurs procedes de preparation et d'utilisation
WO2000006759A9 (fr) Systemes d'administration et plasmides anti-angiogenese et leurs procedes de preparation et d'utilisation
Avalosse et al. Gene therapy for cancer
CA2173495A1 (fr) Traitement de tumeurs par la transformation genetique des cellules tumorales a l'aide de genes codants des marqueurs selectifs negatifs et des cytokines
US20220213160A1 (en) Protein heterodimer and use thereof
Missol et al. Introduction of murine Il-4 gene into B16 (F10) melanoma tumors by direct gene transfer with DNA-liposome complexes
CZ20003807A3 (cs) DNA konstrukt, izolovaná molekula nukleové kyseliny, homologně rekombinantní buňka a její použití, způsob pozměnění exprese endogenního G-CSF genu a způsob produkce G-CSF
KR20240013750A (ko) Ras 돌연변이를 표적으로 하는 t 세포 수용체 및 그의 용도
Eslahi et al. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy
CN109748974B (zh) 一种基因修饰的树突状细胞疫苗的制备及应用
Hussein The potential applications of gene transfer in the treatment of patients with cancer: a concise review

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead